{"id":"W2794297331","doi":"10.1200/jco.2018.36.6_suppl.410","title":"Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Docetaxel; Medicine; Pembrolizumab; Internal medicine; Paclitaxel; Regimen; Clinical endpoint; Oncology; Chemotherapy; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006408352,0.001103993,0.002249935,0.0005910202,0.001015693,0.001407421,0.0008238943,0.002237277,0.005834573],"category_scores_gemma":[0.003689146,0.000597832,0.002651146,0.0005873445,0.0005736795,0.001512621,0.001058763,0.004367123,0.001269334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001009166,"about_ca_system_score_gemma":0.0009820262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00124416,"about_ca_topic_score_gemma":0.002303551,"domain_scores_codex":[0.9983563,0.0006556986,0.0001372767,0.0002864743,0.0002228013,0.0003415397],"domain_scores_gemma":[0.9966574,0.0006541491,0.0008379087,0.0003489234,0.0002540683,0.001247708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8909504,0.01271338,0.03315257,0.0004791641,0.004348469,0.0003961542,0.0002061191,0.00185282,0.00471134,0.0001373919,0.01305942,0.03799282],"study_design_scores_gemma":[0.3231856,0.2995624,0.349337,0.0001690778,0.007616573,0.000751992,0.0002068503,0.001964322,0.003245866,0.0004822452,0.01334663,0.0001314532],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9728057,0.004031061,0.000871737,0.001004442,0.000357357,0.001788522,0.01492505,0.00008441127,0.004131641],"genre_scores_gemma":[0.9613502,0.001077285,0.0006004543,0.002219881,0.0002686415,0.001520214,0.02894515,0.00003450338,0.003983661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006408352,"threshold_uncertainty_score":0.03389096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1505913343865634,"score_gpt":0.4969103208469841,"score_spread":0.3463189864604207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}